256935-76-9

Basic information

• Product Name: Imidazo[1,5-a]pyridine-6-carboxylic acid (9CI)
• Synonyms: Imidazo[1,5-a]pyridine-6-carboxylic acid (9CI);H-imidazo[1,5-a]pyridine-6-carboxylic acid;IMIDAZO[1,5-A]PYRIDINE-6-CARBOXYLIC ACID
• CAS NO: 256935-76-9
• Molecular Formula: C₈H₆N₂O₂
• Molecular Weight: 162.14544
• Product Categories: AMINETERTIARY;Heterocycle-Pyridine series
• Mol File: 256935-76-9.mol

Chemical Properties

• Appearance: /
• Density: 1.41
• Refractive Index: 1.676
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 0.80±0.41(Predicted)
• CAS DataBase Reference: Imidazo[1,5-a]pyridine-6-carboxylic acid (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Imidazo[1,5-a]pyridine-6-carboxylic acid (9CI)(256935-76-9)
• EPA Substance Registry System: Imidazo[1,5-a]pyridine-6-carboxylic acid (9CI)(256935-76-9)

Safety Data

• Hazardous Substances Data: 256935-76-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
Imidazo[1,5-a]pyridine-6-carboxylic acid (9CI) is utilized as a building block in the synthesis of various biologically active compounds. Its unique structure allows for the creation of diverse pharmaceutical agents with potential therapeutic applications.
Used in Medicinal Chemistry Research:
Imidazo[1,5-a]pyridine-6-carboxylic acid (9CI) serves as a valuable subject for researchers and chemists to study and understand its properties and potential uses. By exploring its pharmacological activities, Imidazo[1,5-a]pyridine-6-carboxylic acid (9CI) may contribute to the advancement of pharmaceuticals and medicinal chemistry, offering new avenues for drug discovery and development.

InChI:InChI=1/C8H6N2O2/c11-8(12)6-1-2-7-3-9-5-10(7)4-6/h1-5H,(H,11,12)

Upstream product

• 139183-89-4 methyl imidazo[1,5-a] pyridine-6-carboxylate 
• 139183-88-3 methyl 6-formylaminomethylnicotinate 

Relevant articles and documents

Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease

The invention provides compounds of Formula I: 1These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat conditions or diseases in which α7 is known to be involved.

Synthesis and biological evaluation of 2-Indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent

A series of indole containing oxazolines has been discovered as a result of structural modifications of the lead compound A-105972. The compounds exert their anticancer activity through inhibition of tubulin polymerization by binding at the colchicine site. A-289099 was identified as an orally active antimitotic agent active against various cancer cell lines including those that express the MDR phenotype. The anticancer activity, pharmacokinetics, and an efficient and enantioselective synthesis of A-289099 are described.